Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Merck & Co., Inc. — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.11, while Merck & Co., Inc. trades at $123.45 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | MRK | |
|---|---|---|
52-Week High | $41.63 | $129.52 |
52-Week Low | $31.99 | $77.60 |
Market Cap | — | $298.31B |
Sector | — | Health |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.
The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.
Merck (MRK) trades at $123.43, down 0.48% on the day, with a bullish technical signal and strong institutional buying. Recent earnings beat expectations in three of the last four quarters, with Q2 2026 results pending. The company's acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, while solid profitability metrics include a net income margin of 13.59% and ROE of 18.97% for 2025.
The outlook remains positive with a consensus price target of $137.30, implying 11% upside. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. Analysts are predominantly bullish, with 68% recommending Buy, supported by robust cash flow and strategic M&A activity to drive long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
